Tabuľka
Náklady na výnimkové lieky* EMA OMP 9 876 289 22,7%
mil. € VYN 19 432 059 44,6%
Podiel v 2020 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 CAGR AVASTIN 4 240 432 9,7%
Others 9 975 626 22,9%
EMA OMP 23% 9,352 8,944 9,398 9,489 9,876 13,200 14,400 15,500 16,800 18,400 13%
In-label 45% 18,375 17,572 18,464 18,643 19,432 23,800 31,500 27,600 30,000 31,800 10%
Avastin 10% 4,240 4,000 4,000 3,800 3,600 2,900
Others 23% 9,976 10,000 10,000 10,000 10,000 9,600 In-label 29 308 348 67,3%
SPOLU 41,200 39,400 41,400 41,800 43,524 51,000 59,900 56,900 60,400 62,700
-4% 5% 1% 17,2% 17,5% -5,0% 6,2% 3,8%
Zdroj:
* ZP, MZ SR, odhad pre 2021-2025
Tabuľka
Náklady na výnimkové lieky - dopad novely 363/2011
mil. €
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
EMA OMP 23% 9,352 8,944 9,398 9,489 9,876 13,200 14,400 11,000 6,900 1,400 -32%
In-label 45% 18,375 17,572 18,464 18,643 19,432 23,800 32,600 12,300 6,000 2,000 -37%
Avastin 10% 4,240 4,000 4,000 3,800 3,600 2,900
Others 23% 9,976 10,000 10,000 10,000 10,000 9,600
SPOLU 41,200 39,400 41,400 41,800 43,524 51,000 61,000 37,100 26,500 15,900
-4% 5% 1% 17,2% 19,6% -39,2% -28,6% -40,0%
* ZP, MZ SR, odhad pre 2021-2025 1,100 -19,800 -33,900 -46,800
10,000 -13,900 -24,500 -35,100
3,9% 2,9% 1,9%
Tabuľka 50,700 38,280 25,080
Úspory z režimu výnimkových liekov* 1280 1300 1320 1320
mil. €
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
EMA OMP 0,000 -4,500 -9,900 -17,000
In-label 1,100 -15,300 -24,000 -29,800
Avastin 0,000 0,000 0,000 0,000
Others 0,000 0,000 0,000 0,000
SPOLU 1,100 -19,800 -33,900 -46,800
Zdroj:
* ZP, MZ SR